|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
2000
|
|
gptkbp:ATCCode
|
A03AE01
|
|
gptkbp:brand
|
Lotronex
|
|
gptkbp:CASNumber
|
122852-69-1
|
|
gptkbp:contraindication
|
inflammatory bowel disease
history of constipation
history of ischemic colitis
|
|
gptkbp:developer
|
gptkb:Glaxo_Wellcome
|
|
gptkbp:eliminationHalfLife
|
1.5 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C17H18N4O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
alosetron
|
|
gptkbp:indication
|
severe diarrhea-predominant IBS in women
|
|
gptkbp:KEGGID
|
D07441
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
5-HT3 receptor antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201202
2055
2138
DB00969
|
|
gptkbp:reintroduction
|
reintroduced to US market in 2002 with restrictions
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
abdominal pain
constipation
ischemic colitis
|
|
gptkbp:status
|
FDA approved
|
|
gptkbp:synonym
|
Lotronex
alosetron hydrochloride
|
|
gptkbp:UNII
|
QF5P1WUB5K
|
|
gptkbp:usedFor
|
irritable bowel syndrome
|
|
gptkbp:withdrawn
|
withdrawn from US market in 2000
|
|
gptkbp:bfsParent
|
gptkb:IBS-D
|
|
gptkbp:bfsLayer
|
7
|